Complete index

Every compound we track, A–Z

The full alphabetical directory of every peptide and related substance in the atlas, with its current U.S. regulatory status. Organized by name here; the home page groups the same facts by status, and /jurisdictions cuts them by regulator.

18 compounds tracked · updated ET

  • In limbo14
  • Restricted3
  • Compounding-legal1
  1. BPC-157Body Protection Compound 157 · BepecinIn limboPCAC recommended listing (8-6, Jul 23, 2026) - advisory only; still not on the 503A list
  2. CJC-1295Modified GRF 1-29 · DAC:GRFIn limboPCAC voted against listing (Dec 2024); off Category 2, not on the 503A list
  3. Emideltide (DSIP)Delta sleep-inducing peptide · DSIPIn limboPCAC voted against listing (6-7, Jul 24, 2026); not on the 503A list
  4. EpitalonEpithalon · EpithaloneIn limboPCAC recommended listing (reported 7-4, Jul 24, 2026) - advisory only; still not on the 503A list
  5. GHK-CuCopper tripeptide-1 · Copper peptideIn limboInjectable removed from Category 2, not on the 503A list; PCAC review expected before end of Feb 2027Next: Feb 28, 2027 · in 182 days
  6. IpamorelinIpamorelin acetateIn limboPCAC voted against listing (Oct 2024); off Category 2, not on the 503A list
  7. KPVLysine-proline-valine · Lys-Pro-ValIn limboPCAC recommended listing (8-6, Jul 23, 2026) - advisory only; still not on the 503A list
  8. Melanotan IIMT-II · MT-2In limboOff Category 2, not on the 503A list; PCAC review expected before end of Feb 2027Next: Feb 28, 2027 · in 182 days
  9. MOTS-cMOTs-C · Mitochondrial-derived peptideIn limboPCAC recommended listing (7-5, Jul 23, 2026) - advisory only; still not on the 503A list
  10. NAD+Nicotinamide adenine dinucleotide · NADIn limboNot on the finalized 503A list; no federal ban; compounded in a gray area
  11. RetatrutideLY3437943 · GIP/GLP-1/glucagon triple agonistRestrictedInvestigational only - no approved form exists anywhere; cannot be compounded; FDA warning letters target sellersNext: Mar 31, 2027 · in 213 days
  12. SelankSelank acetate · TP-7In limboRemoved from Category 2 (2024); not on the 503A list; no scheduled review
  13. Semaglutide (compounded)Ozempic · WegovyRestrictedEnforcement discretion ended; routine compounding no longer permitted. 503B exclusion proposed - comments closed Jul 30, 2026, decision pending
  14. SemaxSemax acetateIn limboPCAC recommended listing (8-5, Jul 24, 2026) - advisory only; still not on the 503A list
  15. SermorelinGRF 1-29 · GerefCompounding-legalCategory 1 of the interim 503A list - compoundable with a prescription
  16. TB-500 (Thymosin Beta-4)TB-500 · Thymosin Beta-4In limboPCAC recommended listing (8-6, Jul 23, 2026) - advisory only; still not on the 503A list
  17. Thymosin Alpha-1Thymalfasin · ZadaxinIn limboOff Category 2, never in Category 1; PCAC declined Dec 2024
  18. Tirzepatide (compounded)Mounjaro · ZepboundRestrictedEnforcement discretion ended; broad compounding no longer permitted. 503B exclusion proposed - comments closed Jul 30, 2026, decision pending

What the statuses mean

Under review
Actively before the FDA advisory committee; a decision is pending and the status can move.
In limbo
Nominated or removed from a restricted list but NOT approved - the headline implies a change, but the legal reality did not move.
Restricted
Prescription-only, banned, controlled, or under active FDA enforcement.
Compounding-legal
On the FDA 503A bulk-substances list; a licensed pharmacy may compound it. This is not the same as being an FDA-approved drug.
Unscheduled
No specific federal action; unaddressed at this time.

Status is never reduced to “legal / illegal.” Each badge pairs a color with a word, and every entry links to the primary source behind it. How we track it.